I-131 remnant ablation in differentiated thyroid cancer-optimal treatment with maximal outcome
Withdrawn
- Conditions
- differentiated thyroid carcinomathyroid cancer10043739
- Registration Number
- NL-OMON36661
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 144
Inclusion Criteria
low and high risk patients (AJCC 6) with recently diagnosed histological proven differentiated thyroid cancer, who have to be treated with ablation therapy
aged 18 years or older
not pregnant
not major concurrent diseases (such as stable cardiovascular disease, concurrent malignancy treated < 5 years) leading to a reduced survival < 1 year
normal renal function
Exclusion Criteria
Stage T4
Stage M1 when known before ablation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoint of successful ablation is defined as: rhTSH Tg<1ng/ml,<br /><br>negative rhTSH dx WBS, negative neck US and negative Tg antibodies.<br /><br><br /><br>In case of TgAb or Tg < 1 ng/ml at tthe time of ablation, a second high dose of<br /><br>I131 will be given according to the Dutch guidelines. In these patients a<br /><br>succesfull ablation will be defined as a post treatment scintigraphy with no<br /><br>visible uptake in the original thyroid bed</p><br>
- Secondary Outcome Measures
Name Time Method <p>not applicable</p><br>